RxSight
General Information | |
Business: | We are a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Our proprietary RxSight Light Adjustable Lens system (“RxSight system”), comprised of our RxSight Light Adjustable Lens (“LAL”), RxSight Light Delivery Device (“LDD”) and accessories, is the first and only commercially available intraocular lens (“IOL”) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Our LAL is made of proprietary photosensitive material that changes shape in response to specific patterns of ultraviolet (“UV”) light generated by our LDD. With the RxSight system, the surgeon performs a standard cataract procedure to implant the LAL, determines refractive error with patient input after healing is complete, and then uses the LDD to modify the lens with the exact amount of visual correction needed to achieve the patient’s desired vision outcomes. |
Industry: | OPHTHALMIC GOODS |
Employees: | 171 |
Founded: | 1997 |
Contact Information | |
Address | 100 Columbia Aliso Viejo, CA 92656, US |
Phone Number | (949) 521-7830 |
Web Address | http://www.rxsight.com |
View Prospectus: | RxSight |
Financial Information | |
Market Cap | $450.84mil |
Revenues | $15.27 mil (last 12 months) |
Net Income | $4.27 mil (last 12 months) |
IPO Profile | |
Symbol | RXST |
Exchange | NASDAQ |
Shares (millions): | 7.4 |
Price range | $16.00 - $16.00 |
Est. $ Volume | $117.6 mil |
Manager / Joint Managers | J.P. Morgan/ BofA Securities/ SVB Leerink/ Wells Fargo Securities/ BTIG |
CO-Managers | - |
Expected To Trade: | 7/30/2021 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |